Jan Jansen and Marion Campbell present the results of the UK-REBOA trial, investigating the use of REBOA in trauma patients. They discuss the enrollment process, data collection, and clinical trial results. The podcast also covers the importance of reducing time to hemostasis in hemorrhagic deaths and the challenges of managing blunt trauma injuries. Additionally, they explore the difficulties of intubation in children and evaluating efficacy.
The UK-REBOA trial found that the addition of Riboa to standard care increased 90-day all-cause mortality, specifically due to hemorrhage, highlighting the need for further research on trauma laparotomy patients who may benefit from hemorrhage control interventions.
The study acknowledged the learning curve and volume issues associated with introducing Riboa, suggesting that future studies in high-volume centers with stringent accreditation and credentialing processes could address these challenges.
The podcast emphasizes the challenges of implementing Roboa in pre-hospital settings, the importance of timing and decision-making, and the need for continuous research to explore its potential benefits and effectiveness in specific patient subsets.
Deep dives
Main Findings of the Podcast
The UK-Riboa trial investigated the use of riboa in trauma patients with severe non-compressible torso hemorrhage. The trial found that the addition of Riboa to standard care increased 90-day all-cause mortality with a high probability. Patients in the standard care plus Riboa arm were more likely to die from hemorrhage and more likely to die from hemorrhage early on in their treatment. The study also showed that fewer patients in the standard care plus Riboa arm progressed to hemorrhage control procedures, possibly due to higher mortality rates before the procedures could be performed.
Learning Curve and Volume Issues
The study acknowledged the learning curve and volume issues associated with introducing a new intervention like Riboa in a highly complex and time-sensitive setting. While efforts were made to mitigate the learning curve through extensive training, the small number of patients and centers involved in the study limited the ability to fully address this issue. Future studies in high-volume centers with stringent accreditation and credentialing processes could help better understand and address the learning curve and volume issues associated with Riboa.
Potential Focus on Trauma Laparotomy Patients
The study highlighted the need for further research specifically targeting trauma laparotomy patients who may benefit from hemorrhage control interventions like Riboa. The epidemiology of trauma laparotomies, time to intervention, and the importance of identifying the site of bleeding before intervention were discussed. It was suggested that future studies focus on this patient population to improve outcomes for patients who are running out of time due to preventable hemorrhagic deaths.
Implications and Limitations
The study provided important insights into the effectiveness and impact of using Riboa in trauma patients. However, there were certain limitations identified, such as logistical challenges and potential impact on clinical care due to the process of randomization and data entry. Imbalances in baseline characteristics and the small number of patients in certain groups were also acknowledged. The study emphasized the need for further research, collaborations, and ongoing efforts to improve hemorrhage control and outcomes in trauma patients.
Roboa as an Intervention in Trauma Settings
The podcast episode discusses the use of Roboa (Resuscitative Endovascular Balloon Occlusion of the Aorta) as an intervention in trauma settings. The main focus is on the findings from a trial conducted in the UK, which aimed to evaluate the effectiveness of Roboa in improving patient outcomes. The trial revealed that implementing Roboa did not appear to save lives and there was a preponderance of evidence suggesting potential harm. The discussion also touches upon the challenges of implementing Roboa in pre-hospital settings, where time constraints and the need for early hemorrhage control are critical.
Considerations and Limitations of Roboa
The podcast highlights various considerations and limitations associated with the use of Roboa in trauma care. One of the main considerations is the decision-making process for deploying Roboa, as timing is crucial to avoid an intervention that may not be needed or missing the window of opportunity for benefit. The discussion also mentions the importance of early common femoral access, the challenges of balancing under-triage and over-triage in trauma care, and the potential value of Roboa in refractory cardiac arrest cases. Additionally, the episode emphasizes the need for continuous research to explore the potential benefits and patient subsets where Roboa may be effective.
Jan Jansen (Birmingham, USA) & Marion Campbell (Aberdeen) present the results of the UK-REBOA trial, investigating the use of REBOA in trauma patients with severe non-compressible torso haemorrhage. The editorial is delivered by John Holcomb (also from Birmingham, USA) and the session is chaired by Catriona Kelly from Dublin. The panel discussing the trial are Diana Cimpoesu (Ilsa, Romania), Caroline Leech (Coventry), Stephen Bernard (Melbourne) and Roger Lewis (Los Angeles).
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode